Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Prevention

Cancer Prevention

Cancer Prevention

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Sensitivity, Specificity, and Predicted Value

Sensitivity, Specificity, and Predicted Value

In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.

European urology·2024

Same author

Successful completion of large, low-cost randomized cancer trials at an academic cancer center.

Clinical trials (London, England)·2024

Same author

Testosterone Therapy in Men After Radical Prostatectomy for Low-Intermediate Organ-Confined Prostate Cancer.

The Journal of urology·2024

Same author

Re: Early Prostate Cancer Deaths Among Men with Higher vs Lower Genetic Risk.

European urology·2024

Same author

Transperineal vs Transrectal Prostate Biopsy-The PREVENT Randomized Clinical Trial.

JAMA oncology·2024

Same author

Clinical utility of an artificial intelligence radiomics-based tool for risk stratification of pulmonary nodules.

JNCI cancer spectrum·2024

Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

Peter R Carroll¹, J Kellogg Parsons², Gerald Andriole³

¹UCSF Helen Diller Family Comprehensive Cancer Center

Journal of the National Comprehensive Cancer Network : JNCCN

|May 11, 2016

Summary

This summary is machine-generated.

The National Comprehensive Cancer Network (NCCN) Guidelines offer updated prostate cancer screening recommendations. They aim to reduce unnecessary procedures and overdiagnosis, focusing on high-risk groups and improving biopsy accuracy.

More Related Videos

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Mar 21, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

Oncology
Urology
Preventive Medicine

Background:

Prostate cancer screening guidelines aim to detect cancer early while minimizing harms like unnecessary procedures and overdetection of indolent disease.
The National Comprehensive Cancer Network (NCCN) developed guidelines for prostate cancer early detection in asymptomatic men.
The 2016 update focused on refining screening strategies and biopsy approaches.

Framework:

The NCCN Guidelines for Prostate Cancer Early Detection provide evidence-based recommendations.
The guidelines emphasize shared decision-making between patients and clinicians.
Key updates address screening in specific high-risk populations and optimizing diagnostic pathways.

Implementation:

Recommendations cover screening initiation, frequency, and cessation based on risk factors.
The update includes specific considerations for African American men and BRCA1/2 mutation carriers.
Strategies to refine patient selection for initial and repeat prostate biopsies are detailed.

Implications:

Improved patient selection for biopsies can reduce unnecessary procedures and healthcare costs.
Enhanced biopsy specificity may lead to more accurate diagnosis and appropriate treatment.
These guidelines support personalized prostate cancer screening and early detection efforts.